In general, DPP-4 inhibitors did not show an increased risk of CV death, nonfatal myocardial infarction, or nonfatal stroke when compared to placebo, although saxagliptin had an association with an increased rate of hospitalization for heart failure [96]. The gene discussed is DPP4; the disease is myocardial infarction.